44 unknown. 44 Phase 2, 22 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 44 | Unknown 44 |
| Phase 1 | 22 | Unknown 22 |
| Phase 3 | 3 | Unknown 3 |
Follow Hematologic Neoplasms: new trials by email Literature Review of Hematologic Neoplasms trials Research Report on Hematologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM Thymoglobulin Injectable Product - Hematological Malignancy | Phase 2 | Unknown | Institut Paoli-Calmettes | 27 | 2024-03-31 | 2024-02-20 |
| Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade Cyclophosphamid - Graft-versus-host Disease, Hematological Malignancies | Phase 2 | Unknown | Beijing 302 Hospital | 22 | 2024-02-28 | 2024-02-20 |
| Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide Allogeneic T cell progenitors, cultured ex-vivo - Hematological Malignancies | Phase 1 / Phase 2 | Unknown | Smart Immune SAS | 40 | 2023-06-06 | 2023-09-25 |
| Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies umbilical cord derived mesenchymal stem cells - Hematologic Neoplasms, Neutropenia | Phase 1 / Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 181 | 2023-01-01 | 2023-01-05 |
| Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome Ruxolitinib - Bronchiolitis Obliterans Syndrome, Hematologic Malignancy | Phase 2 | Unknown | First Affiliated Hospital of Zhejiang University | 50 | 2022-06-01 | 2022-10-19 |
| Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation - Hematologic Malignancy | Phase 1 / Phase 2 | Unknown | Sichuan University | 56 | 2022-03-01 | 2022-03-15 |
| Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT MIT-001, normal saline - Oral Mucositis, Lymphoma | Phase 2 | Unknown | MitoImmune Therapeutics | 60 | 2022-02-01 | 2024-05-29 |
| A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies CN202 - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Unknown | Curon Biopharmaceutical (Australia) Co Pty Ltd | 164 | 2021-10-22 | 2021-08-31 |
| Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT venetoclax combining with fludarabine and melphalan - Hematologic Malignancy, Older Patients | Phase 2 | Unknown | First Affiliated Hospital of Zhejiang University | 50 | 2021-10-07 | 2021-10-27 |
| Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS Azacitidine, all trans retinoic acid - AML, MDS | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 180 | 2021-05-01 | 2022-01-03 |
| Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients Azacitidine in Combination With Venetoclax - Hematologic Malignancy, Stem Cell Transplant Complications | Phase 2 | Unknown | First Affiliated Hospital of Zhejiang University | 95 | 2021-03-19 | 2023-02-21 |
| Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions CAR-T cells - Hematological Malignancies | Phase 1 / Phase 2 | Unknown | Zhejiang University | 50 | 2021-03-01 | 2021-03-10 |
| A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia Cyclophosphamide-Fludarabine (Cy/Flu), oNKord® - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Glycostem Therapeutics BV | 33 | 2020-12-08 | 2022-06-21 |
| GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide Methotrexate Injectable Solution - Graft Vs Host Disease, Hematopoietic Neoplasm | Phase 1 / Phase 2 | Unknown | University of Sao Paulo General Hospital | 47 | 2020-10-07 | 2021-09-14 |
| Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours CAR-T cell therapy - Hematological Malignancy | Phase 2 / Phase 3 | Unknown | Shanxi Bethune Hospital | 30 | 2020-06-15 | 2024-02-02 |
| Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells Metoprolol, metoprolol, infliximab, etanercept, tocilizumab and/or other agents - Solid Tumor, Hematological Malignancy | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2019-09-15 | 2022-04-13 |
| Combination Chemotherapy in Patients With Newly Diagnosed BPDCN Chemotherapy - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 2 | Unknown | Centre Hospitalier Universitaire de Besancon | 26 | 2019-05-02 | 2024-02-08 |
| Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant donor-derived CIK cells - Relapsed Hematologic Malignancy | Phase 1 / Phase 2 | Unknown | A.O. Ospedale Papa Giovanni XXIII | 20 | 2019-01-13 | 2021-12-23 |
| Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT Imipenem - Antibacterial Prophylaxis, Hematological Malignancies | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 250 | 2018-12-01 | 2018-11-07 |
| Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing HSCT Cholecalciferol - Hematologic Neoplasms | Phase 2 | Unknown | Seoul National University Hospital | 88 | 2017-10-01 | 2017-10-25 |
Showing 20 of 44. Sign in to see all of them.
Graft vs Host Disease (4) · Leukemia, Myeloid, Acute (4) · Lymphoma, Mantle-Cell (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Follicular (3) · Lymphoma, Large B-Cell, Diffuse (3) · Multiple Myeloma (3) · Polycythemia Vera (3) · Recurrence (3) · Leukemia (2) · Leukemia, Prolymphocytic (2) · Lymphoma (2) · Myelodysplastic Syndromes (2) · Neoplasms (2)
Hemic and Lymphatic Diseases (44) · Neoplasms by Site (44) · Hematologic Diseases (43) · Neoplasms (42) · Immune System Diseases (12) · Neoplasms by Histologic Type (11) · Pathological Conditions, Signs and Symptoms (11) · Pathologic Processes (10) · Immunoproliferative Disorders (7) · Leukemia (7) · Lymphatic Diseases (7) · Lymphoproliferative Disorders (7) · Bone Marrow Diseases (6) · Disease Attributes (6) · Lymphoma (6)
Cyclophosphamide (4) · fludarabine (3) · Azacitidine (2) · Immunotherapy, Adoptive (2) · Mycophenolic Acid (2) · Antilymphocyte Serum (1) · Busulfan (1) · CF regimen (1) · Cholecalciferol (1) · Cord Blood Stem Cell Transplantation (1) · Cyclosporine (1) · Drug Therapy (1) · Etanercept (1) · Hematopoietic Stem Cell Transplantation (1) · Histone Deacetylase Inhibitors (1)
Chinese PLA General Hospital (4) · First Affiliated Hospital of Zhejiang University (3) · A.O. Ospedale Papa Giovanni XXIII (2) · Hospices Civils de Lyon (2) · Ronald Hoffman (2) · Seoul National University Hospital (2) · Beijing 302 Hospital (1) · Cancer Research UK (1) · Cellect Biotechnology (1) · Centre Hospitalier Universitaire de Besancon (1) · Ciusss de L'Est de l'Île de Montréal (1) · Copenhagen University Hospital at Herlev (1) · Curon Biopharmaceutical (Australia) Co Pty Ltd (1) · European Institute of Oncology (1) · Glycostem Therapeutics BV (1)
China (15) · France (6) · Italy (5) · Israel (3) · South Korea (3) · Belgium (2) · Netherlands (2) · United Kingdom (2) · United States (2) · Australia (1) · Brazil (1) · Canada (1) · Denmark (1) · Germany (1) · Sweden (1)
Yi Luo, M.D. (3) · Alessandro Rambaldi, MD (2) · Ronald Hoffman, MD (2) · Andrea Velardi, Prof (1) · David Ritchie, FRACP, PhD (1) · Denis-Claude Roy, MD PhD (1) · Domenico Russo, Full Professor (1) · Gary Richardson (1) · Giancarlo Fatobene, MD (1) · Han Yue, Ph.D (1) · Hans C Hasselbalch, MD (1) · Jiang Cao, Doctor (1)
PMID 12171484, PMID 16732175, PMID 18468541, PMID 18703664, PMID 18820709, PMID 20350611, PMID 21393326, PMID 21417678, PMID 24140121, PMID 25444722, PMID 25563429, PMID 29263894, PMID 32245502, PMID 34515338, PMID 34700343, PMID 38304826, PMID 38485149, PMID 42159161
2009 (1), 2019 (1), P01CA108671 (1)